Xyloglucan, Hibiscus and Propolis for the prevention of Urinary Tract Infections: results of in vitro studies

Data de publicació

2020-06-08T07:56:27Z

2020-06-08T07:56:27Z

2017-03-06

2020-06-08T07:56:28Z

Resum

Aim: To assess the properties of a medical device containing xyloglucan, propolis and hibiscus to create a bioprotective barrier to avoid the contact of uropathogenic Escherichia coli strains on cell walls in models of intestinal (CacoGoblet) and uroepithelial (RWPE-1) cells (derived from normal human prostate epithelium). Materials & methods: Two uropathogenic E. coli strains (expressing type 1 fimbriae and P fimbriae) were used to assess, by electronic microscopy and ELISA, the barrier properties of the medical device. The antimicrobial activity was assessed in broth dilution assays. Results: The three components (xyloglucan, propolis and hibiscus) did not alter E. coli cell integrity in intestinal and uroepithelial cell models and were devoid of antibacterial activity. The three components avoided bacterial contact in both cell monolayers. Conclusion: The nonpharmacological barrier properties of xyloglucan, propolis and hibiscus confirm the role of the medical device for the management of urinary tract infections.

Tipus de document

Article


Versió acceptada

Llengua

Anglès

Publicat per

Future Medicine

Documents relacionats

Versió postprint del document publicat a: https://doi.org/10.2217/fmb-2017-0015

Future Microbiology, 2017, vol. 12, p. 721-731

https://doi.org/10.2217/fmb-2017-0015

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

(c) Future Medicine, 2017

Aquest element apareix en la col·lecció o col·leccions següent(s)